Q4 2024 Travere Therapeutics Inc Earnings Call Transcript

Feb 20, 2025 / 09:30 PM GMT

Release Date Price: $23.58 (+1.07%)

Transcript 10-K8-K

Key Points

Positve

Travere Therapeutics Inc (TVTX) achieved full FDA approval for Phil Spari for IgA nephropathy, marking a significant milestone.
Net sales of Phil Spari grew by nearly 40% in the fourth quarter compared to the third quarter, indicating strong commercial execution.
The company plans to submit an SNDA for a potential FSGS indication, which could lead to the first FDA-approved therapy for FSGS by year-end.
Travere Therapeutics Inc (TVTX) is well-capitalized following successful financing, with cash equivalents and marketable securities totaling $370.7 million.
The company is making progress in expanding Phil Spari's potential beyond IgA nephropathy, with plans to initiate new studies and expand existing ones.

Negative

The company faces potential competition in the IgA nephropathy space from new entrants like Novartis, which could impact Phil Spari's market share.
There are ongoing challenges with the manufacturing scale-up of the peg debatinenace program, delaying the restart of enrollment in the phase 3 harmony study.
Travere Therapeutics Inc (TVTX) reported a net loss of $60.3 million for the fourth quarter, highlighting ongoing financial challenges.
The company anticipates further headwinds in sales for Thiola due to generic competition.
There is uncertainty regarding the future of the accelerated approval pathway for IgA nephropathy, which could impact the company's strategic plans.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TVTX.OQ - Travere Therapeutics Inc
Q4 2024 Travere Therapeutics Inc Earnings Call
Feb 20, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the revere Therapeutics 4th quarter and full year 2024 financial results conference call. Today's call is being recorded at this time. I would like to turn the conference call over to Victoria Prescott, manager of investor relations. Please go ahead, Victoria.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Chloe. Good afternoon and welcome to Travere Therapeutics, 4th quarter and full year 2024 Financial results and corporate update call.

Thank you all for joining.

Today's call will be led by Doctor Eric Dube,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.